SAN DIEGO--(BUSINESS WIRE)--June 5, 2006--Ligand Pharmaceuticals Incorporated (Pink Sheets:LGND - News; the "Company" or "Ligand") -- Results of retrospective analysis in large trials in first line NSCLC and final analysis of a 3rd line NSCLC trial were presented Sunday, June 4th at the annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta. Lung cancer data presented yesterday include:
